173 related articles for article (PubMed ID: 17324746)
1. Sodium, arterial stiffness, and cardiovascular mortality in hypertensive rats.
Mercier N; Labat C; Louis H; Cattan V; Benetos A; Safar ME; Lacolley P
Am J Hypertens; 2007 Mar; 20(3):319-25. PubMed ID: 17324746
[TBL] [Abstract][Full Text] [Related]
2. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet.
Labat C; Lacolley P; Lajemi M; de Gasparo M; Safar ME; Benetos A
Hypertension; 2001 Sep; 38(3):439-43. PubMed ID: 11566919
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
Dong YF; Kataoka K; Tokutomi Y; Nako H; Nakamura T; Toyama K; Sueta D; Koibuchi N; Yamamoto E; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2011 Nov; 339(2):358-66. PubMed ID: 21807884
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Yamamoto E; Kataoka K; Shintaku H; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2569-75. PubMed ID: 17932313
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Biala A; Finckenberg P; Korpi A; Loytainen M; Martonen E; Levijoki J; Mervaala E
J Physiol Pharmacol; 2011 Jun; 62(3):275-85. PubMed ID: 21893687
[TBL] [Abstract][Full Text] [Related]
6. [The effect and mechanism of felodipine and valsartan on a novel salt-sensitive hypertensive rat induced by sensory denervation].
Han YF; Su CJ; Ou BR
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Mar; 33(3):255-9. PubMed ID: 15929825
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
8. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Ke YS; Tao YY; Yang H; Yu GH
Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Sironi L; Gelosa P; Guerrini U; Banfi C; Crippa V; Brioschi M; Gianazza E; Nobili E; Gianella A; de Gasparo M; Tremoli E
J Pharmacol Exp Ther; 2004 Dec; 311(3):989-95. PubMed ID: 15302895
[TBL] [Abstract][Full Text] [Related]
10. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
11. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
12. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Baumann M; Janssen BJ; Hermans JJ; Peutz-Kootstra C; Witzke O; Smits JF; Struijker Boudier HA
J Hypertens; 2007 Jan; 25(1):207-15. PubMed ID: 17143193
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
[TBL] [Abstract][Full Text] [Related]
14. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
15. Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
Li W; Sun N; Liu W; Chen Y; Yu Y
Chin Med J (Engl); 2002 Mar; 115(3):364-6. PubMed ID: 11940365
[TBL] [Abstract][Full Text] [Related]
16. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Tominaga N; Robert A; Izuhara Y; Ohtomo S; Dan T; Chihara K; Kurokawa K; Van Ypersele de Strihou C; Miyata T
Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Duprez DA; Florea ND; Jones K; Cohn JN
J Am Coll Cardiol; 2007 Aug; 50(9):835-9. PubMed ID: 17719468
[TBL] [Abstract][Full Text] [Related]
18. Reduction of salt sensitivity in stroke-prone spontaneously hypertensive rats administered an AT1 receptor antagonist during suckling.
Otani L; Yasumatsu T; Murakami M; Hayashi A; Kimoto K; Murakami T
Am J Hypertens; 2006 Sep; 19(9):979-84. PubMed ID: 16942944
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
20. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Phipps JA; Wilkinson-Berka JL; Fletcher EL
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
